Evidence map›Paper›PMID 25658638›Full record

ArticlePloS one2015

Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.

Skadi Kull, K Melanie Schulz, Jasmin Weisemann, Sebastian Kirchner, Tanja Schreiber, Alexander Bollenbach, P Wojtek Dabrowski, Andreas Nitsche, Suzanne R Kalb, Martin B Dorner and 3 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Review
  6. Conflicting Clinical Presentation of Infection withJournal of pediatrics. Clinical practice · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Fighting Cancer with Bacteria and Their Toxins.International journal of molecular sciences · 2021
    Review
  15. Article
  16. Article
  17. The Distinctive Evolution ofFrontiers in microbiology · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Skadi KullBiological Toxins (ZBS3), Centre for Biological Threats and Special Pathogens, Robert Koch-Institut, Berlin, Germany.
K Melanie SchulzBiological Toxins (ZBS3), Centre for Biological Threats and Special Pathogens, Robert Koch-Institut, Berlin, Germany.
Jasmin WeisemannInstitut für Toxikologie, Medizinische Hochschule Hannover, Hannover, Germany.
Sebastian KirchnerBiological Toxins (ZBS3), Centre for Biological Threats and Special Pathogens, Robert Koch-Institut, Berlin, Germany.
Tanja SchreiberBiological Toxins (ZBS3), Centre for Biological Threats and Special Pathogens, Robert Koch-Institut, Berlin, Germany.
Alexander BollenbachInstitut für Toxikologie, Medizinische Hochschule Hannover, Hannover, Germany.
P Wojtek DabrowskiHighly Pathogenic Viruses (ZBS1), Centre for Biological Threats and Special Pathogens, Robert Koch-Institut, Berlin, Germany.
Andreas NitscheHighly Pathogenic Viruses (ZBS1), Centre for Biological Threats and Special Pathogens, Robert Koch-Institut, Berlin, Germany.
Suzanne R KalbCenters for Disease Control and Prevention, National Center for Environmental Health, Division of Laboratory Sciences, Atlanta, Georgia, United States of America.
Martin B DornerBiological Toxins (ZBS3), Centre for Biological Threats and Special Pathogens, Robert Koch-Institut, Berlin, Germany.
John R BarrCenters for Disease Control and Prevention, National Center for Environmental Health, Division of Laboratory Sciences, Atlanta, Georgia, United States of America.
Andreas RummelInstitut für Toxikologie, Medizinische Hochschule Hannover, Hannover, Germany.
Brigitte G DornerBiological Toxins (ZBS3), Centre for Biological Threats and Special Pathogens, Robert Koch-Institut, Berlin, Germany.
Robert Koch Institute · DEMedizinische Hochschule Hannover · DECenters for Disease Control and Prevention · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Botulism is a severe neurological disease caused by the complex family of botulinum neurotoxins (BoNT). Based on the different serotypes known today, a classification of serotype variants termed subtypes has been proposed according to sequence diversity and immunological properties. However, the relevance of BoNT subtypes is currently not well understood. Here we describe the isolation of a novel Clostridium botulinum strain from a food-borne botulism outbreak near Chemnitz, Germany. Comparison of its botulinum neurotoxin gene sequence with published sequences identified it to be a novel subtype within the BoNT/A serotype designated BoNT/A8. The neurotoxin gene is located within an ha-orfX+ cluster and showed highest homology to BoNT/A1, A2, A5, and A6. Unexpectedly, we found an arginine insertion located in the HC domain of the heavy chain, which is unique compared to all other BoNT/A subtypes known so far. Functional characterization revealed that the binding characteristics to its main neuronal protein receptor SV2C seemed unaffected, whereas binding to membrane-incorporated gangliosides was reduced in comparison to BoNT/A1. Moreover, we found significantly lower enzymatic activity of the natural, full-length neurotoxin and the recombinant light chain of BoNT/A8 compared to BoNT/A1 in different endopeptidase assays. Both reduced ganglioside binding and enzymatic activity may contribute to the considerably lower biological activity of BoNT/A8 as measured in a mouse phrenic nerve hemidiaphragm assay. Despite its reduced activity the novel BoNT/A8 subtype caused severe botulism in a 63-year-old male. To our knowledge, this is the first description and a comprehensive characterization of a novel BoNT/A subtype which combines genetic information on the neurotoxin gene cluster with an in-depth functional analysis using different technical approaches. Our results show that subtyping of BoNT is highly relevant and that understanding of the detailed toxin function might pave the way for the development of novel therapeutics and tailor-made antitoxins.

Indexed as

Disease OutbreaksModels, MolecularAmino Acid SequenceBase SequenceBotulinum Toxins, Type ABotulismClostridium botulinum type AFood, PreservedGermanyHumansMaleMiddle AgedMolecular Sequence DataProtein BindingRNA, Ribosomal, 16SSequence Analysis, DNABotulinum Toxins, Type ARNA, Ribosomal, 16S

Identifiers

PMID25658638
PMCPMC4320087
OpenAlexW2136626748

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.